465 related articles for article (PubMed ID: 29109169)
1. Environmental Triazole Induces Cross-Resistance to Clinical Drugs and Affects Morphophysiology and Virulence of Cryptococcus gattii and C. neoformans.
Bastos RW; Carneiro HCS; Oliveira LVN; Rocha KM; Freitas GJC; Costa MC; Magalhães TFF; Carvalho VSD; Rocha CE; Ferreira GF; Paixão TA; Moyrand F; Janbon G; Santos DA
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109169
[No Abstract] [Full Text] [Related]
2. Roles of Three Cryptococcus neoformans and Cryptococcus gattii Efflux Pump-Coding Genes in Response to Drug Treatment.
Chang M; Sionov E; Khanal Lamichhane A; Kwon-Chung KJ; Chang YC
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378705
[No Abstract] [Full Text] [Related]
3. From the environment to the host: How non-azole agrochemical exposure affects the antifungal susceptibility and virulence of Cryptococcus gattii.
Bastos RW; Freitas GJC; Carneiro HCS; Oliveira LVN; Gouveia-Eufrasio L; Santos APN; Moyrand F; Maufrais C; Janbon G; Santos DA
Sci Total Environ; 2019 Sep; 681():516-523. PubMed ID: 31121401
[TBL] [Abstract][Full Text] [Related]
4. Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans.
Basso LR; Gast CE; Bruzual I; Wong B
J Antimicrob Chemother; 2015 May; 70(5):1396-407. PubMed ID: 25630649
[TBL] [Abstract][Full Text] [Related]
5. Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase.
Carvajal SK; Melendres J; Escandón P; Firacative C
Microbiol Spectr; 2023 Aug; 11(4):e0140323. PubMed ID: 37341584
[TBL] [Abstract][Full Text] [Related]
6. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
[TBL] [Abstract][Full Text] [Related]
7. Heteroresistance of Cryptococcus gattii to fluconazole.
Varma A; Kwon-Chung KJ
Antimicrob Agents Chemother; 2010 Jun; 54(6):2303-11. PubMed ID: 20385871
[TBL] [Abstract][Full Text] [Related]
8. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
[TBL] [Abstract][Full Text] [Related]
9. Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south-eastern Brazil.
Grizante Barião PH; Tonani L; Cocio TA; Martinez R; Nascimento É; von Zeska Kress MR
Mycoses; 2020 Dec; 63(12):1341-1351. PubMed ID: 32869413
[TBL] [Abstract][Full Text] [Related]
10. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
Hagen F; Hare Jensen R; Meis JF; Arendrup MC
Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
[TBL] [Abstract][Full Text] [Related]
11. A subdose of fluconazole alters the virulence of Cryptococcus gattii during murine cryptococcosis and modulates type I interferon expression.
Fontes AC; Bretas Oliveira D; Santos JR; Carneiro HC; Ribeiro NQ; Oliveira LV; Barcellos VA; Paixão TA; Abrahão JS; Resende-Stoianoff MA; Vainstein MH; Santos DA
Med Mycol; 2017 Feb; 55(2):203-212. PubMed ID: 27486215
[TBL] [Abstract][Full Text] [Related]
12. Azole resistance in Cryptococcus gattii from the Pacific Northwest: Investigation of the role of ERG11.
Gast CE; Basso LR; Bruzual I; Wong B
Antimicrob Agents Chemother; 2013 Nov; 57(11):5478-85. PubMed ID: 23979758
[TBL] [Abstract][Full Text] [Related]
13. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii.
Vu K; Gelli A
Med Mycol; 2010 Mar; 48(2):255-62. PubMed ID: 19572230
[TBL] [Abstract][Full Text] [Related]
14. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
Yang F; Gritsenko V; Lu H; Zhen C; Gao L; Berman J; Jiang YY
Microbiol Spectr; 2021 Oct; 9(2):e0072321. PubMed ID: 34585947
[TBL] [Abstract][Full Text] [Related]
15. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil.
Andrade-Silva L; Ferreira-Paim K; Mora DJ; Da Silva PR; Andrade AA; Araujo NE; Pedrosa AL; Silva-Vergara ML
Med Mycol; 2013 Aug; 51(6):635-40. PubMed ID: 23343452
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
Nishikawa H; Fukuda Y; Mitsuyama J; Tashiro M; Tanaka A; Takazono T; Saijo T; Yamamoto K; Nakamura S; Imamura Y; Miyazaki T; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Kohno S; Izumikawa K
J Antimicrob Chemother; 2017 Jun; 72(6):1709-1713. PubMed ID: 28201509
[TBL] [Abstract][Full Text] [Related]
18. In vivo development of fluconazole resistance in serial Cryptococcus gattii isolates from a cat.
Sykes JE; Hodge G; Singapuri A; Yang ML; Gelli A; Thompson GR
Med Mycol; 2017 Jun; 55(4):396-401. PubMed ID: 28339594
[TBL] [Abstract][Full Text] [Related]
19. Molecular identification, antifungal resistance and virulence of Cryptococcus neoformans and Cryptococcus deneoformans isolated in Seville, Spain.
Gago S; Serrano C; Alastruey-Izquierdo A; Cuesta I; Martín-Mazuelos E; Aller AI; Gómez-López A; Mellado E
Mycoses; 2017 Jan; 60(1):40-50. PubMed ID: 27633849
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of heat-shock protein 90 enhances the susceptibility to antifungals and reduces the virulence of Cryptococcus neoformans/Cryptococcus gattii species complex.
Cordeiro RA; Evangelista AJJ; Serpa R; Marques FJF; Melo CVS; Oliveira JS; Franco JDS; Alencar LP; Bandeira TJPG; Brilhante RSN; Sidrim JJC; Rocha MFG
Microbiology (Reading); 2016 Feb; 162(2):309-317. PubMed ID: 26645478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
